Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) operates as a diversified healthcare company with approximately 138,200 full-time equivalent employees worldwide. The company maintains its corporate website at www.jnj.com and conducts business in virtually all countries globally, with a primary focus on products related to human health… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Johnson & Johnson does
In the company’s own words
Johnson & Johnson (NYSE: JNJ) operates as a diversified healthcare company with approximately 138,200 full-time equivalent employees worldwide. The company maintains its corporate website at www.jnj.com and conducts business in virtually all countries globally, with a primary focus on products related to human health and well-being.
The company operates through two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on pharmaceutical products across therapeutic areas including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. Key products in this segment include DARZALEX for multiple myeloma, STELARA for immunological conditions, TREMFYA for psoriasis and inflammatory bowel disease, and XARELTO for anticoagulation. DARZALEX and DARZALEX FASPRO collectively represent approximately 15.0% of total revenues, while STELARA accounts for approximately 6.5% and TREMFYA for approximately 5.5% of revenues.
The MedTech segment develops and manufactures products used in cardiovascular, orthopaedics, surgery, and vision care. This includes electrophysiology products, mechanical circulatory support technologies, neurovascular care solutions, joint reconstruction and trauma products, surgical instrumentation and robotic technologies, and vision care products marketed under the ACUVUE brand and TECNIS intraocular lenses. In October 2025, the company announced its intention to separate its Orthopaedics business, with targeted completion within 18 to 24 months.
The company operates 63 manufacturing facilities and sources from thousands of suppliers worldwide. Johnson & Johnson was incorporated in New Jersey in 1887 and maintains a global workforce distributed across multiple regions. The company's business model emphasizes innovation, with substantial investments in research and development, strategic collaborations, and licensing agreements. The company protects its intellectual property through extensive patent portfolios and trademark registrations across markets where it operates. Its competitive advantages include a diversified product portfolio, established distribution networks, strong brand recognition, and ongoing development of lifecycle management programs for existing products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW BRUNSWICK, NJ
- Fiscal year end
- January
- CIK
- 200406
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Johnson & Johnson — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Johnson & Johnson · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Johnson & Johnson’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Johnson & Johnson’s bonds, as funds hold them
Funds report holding 41 issues of Johnson & Johnson’s debt, $2.68B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.92%, maturing 2026 to 2060.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Johnson & Johnson and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Johnson & Johnson's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Johnson & Johnson's last four quarterly filings that the numbers alone won't show?”